Caplin Point

Caplin Point, established in 1990, is committed to the production of a range of ointments, creams, and other medications for external use. In 1994, the company's initial public offering was 117 times oversubscribed, with proceeds used to set up a manufacturing plant in Pondicherry. Since then, Caplin Point has expanded its product range and increased its production capacity.Caplin Point focuses on emerging markets in Latin America, the Caribbean, France, and South Africa, and is currently one of the leading pharmaceutical suppliers in these regions, holding over 2,000 product licenses globally. The company’s advanced R&D facilities are capable of handling liquid injectables for vials, ampoules, lyophilized vials, and ophthalmic drugs, enabling entry into regulated injectable markets. Its facilities have been approved by the US FDA, EU GMP, Brazil ANVISA, and Colombia INVIMA.